NICODERM CQ OTC
Generic Name and Formulations:
Nicotine 7mg/24hr, 14mg/24hr, 21mg/24hr; transdermal patch (clear or original color).
Indications for NICODERM CQ:
Adjunct in smoking cessation therapy.
Apply to clean, dry, nonhairy site on trunk or upper outer arm; rotate application site. Remove patch after 16 or 24 hours; if vivid dreams or other sleep disturbances occur, remove at bedtime and reapply in AM. >10cigarettes/day: initially one 21mg patch daily for 6 weeks; then one 14mg patch daily for 2 weeks, then one 7mg patch daily for 2 weeks, then stop. ≤10cigarettes/day: initially one 14mg patch daily for 6 weeks then one 7mg patch daily for 2 weeks, then stop.
<18yrs: not recommended.
Concurrent smoking or use of other nicotine products.
Avoid immediately post-MI, in arrhythmias, or severe or worsening angina pectoris. Uncontrolled hypertension. Vasospastic or coronary heart disease. Hepatic or severe renal impairment. Hyperthyroidism. Pheochromocytoma. Stomach ulcers. Diabetes. Allergy to adhesive tape, other skin problems. History of seizures. Discontinue if an allergic reaction occurs. Low doses may be toxic to children and pets. Pregnancy: not recommended (attempt nondrug treatment first). Nursing mothers.
Smoking cessation potentiates theophylline, insulin, β-blockers, pentazocine, oxazepam, tricyclic antidepressants (eg, imipramine), caffeine, acetaminophen, adrenergic antagonists (eg, prazosin, labetalol), others. Smoking cessation antagonizes adrenergic agonists (eg, isoproterenol, phenylephrine), others.
Local irritation, GI upset, headache, dizziness, palpitations, hypertension.
Patch 7mg—14; 14mg—14, 21; 21mg—7, 14, 21
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- The Challenge of Compassion in Modern Healthcare Settings
- Republican Opposition to Obamacare: What's Done, What's to Come
- Lowering Default Pill Counts in EMRs May Effectively Reduce Postoperative Opioid Prescription Numbers
- Steps Taken to Increase Use of Electronic Tools in Medicine
- Daily and Retrospective Pain Measurements Comparable in Hip Osteoarthritis